secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cellectar Biosciences, Inc. (CLRB)
CIK:        0001279704
Form:       8-K
Filed at:   2026-05-14T11:20:27+00:00
Accession:  0001104659-26-060693
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cellectar reports Q1 net loss $5.7M; positive iopofosine data, up to $140M financing
--------------------------------------------------------------------------------

- Q1 net loss $5.7M ($1.33/share) vs $6.6M ($4.30/share) YoY; cash $8.3M at March 31.
- Positive 12-month follow-up from CLOVER WaM: 61.8% MRR, 83.6% ORR, median PFS 13.5 months in r/r WM.
- Completed $35M upfront + up to $105M milestone financing led by Nantahala Capital; Andrew Gu to join board.
- Initiated Phase 1b trial of CLR 125 in triple negative breast cancer; first patient dosed. Dosimetry data expected mid-2026.
- Selected for ASCO 2026 presentation of CLOVER-WaM subgroup data on iopofosine post-BTKi therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1279704/000110465926060693/0001104659-26-060693-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1279704/000110465926060693/tm2614602d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-060693

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer